This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Information on how to access prescribing information and adverse event reporting can be found at the bottom of the page.

ZAVICEFTA® (ceftazidime-avibactam): Broad-spectrum Gram-negative coverage with consistent dosing across indications1–4

Dosing Guide

Preparation Guide

Shelf life and Storage

Shelf life and storage1

Dry powder vial

  • Store in the original package in order to protect from light
  • The vial has a shelf life of three years

After reconstitution

  • Parenteral medicinal products should be inspected visually for particulate matter prior to administration
  • The compatibility of ZAVICEFTA with other medicines has not been established 
  • ZAVICEFTA should not be mixed with or physically added to solutions containing other medicinal products
  • Each vial is for single use only
  • The reconstituted vial should be used immediately

After dilution

  • The SmpC for Great Britain states that chemical and physical in-use stability has been demonstrated for the diluted infusion for up to 24 hours at 2–8°C, followed by up to 12 hours at room temperature at not more than 25°C1(Please note: the SmPC for Northern Ireland states that the dilution should be stored up to 12 hours at 2–8°C, followed by up to 4 hours at room temperature at not more than 25°C)5
  • From a microbiological point of view, the diluted infusion should be used immediately unless reconstitution/dilution has taken place in controlled and validated aseptic conditions

Access results of ZAVICEFTA Phase III clinical trials in adult patients with cUTI, cIAI or HAP/VAP

Access case studies and videos


cIAI, complicated intra-abdominal infection; cUTI, complicated urinary tract infection; HAP, hospital-acquired pneumonia; VAP, ventilator-associated pneumonia; AMR, Antimicrobial Resistance.

Prescribing information
​​​​​​​Zavicefta® (ceftazidime and avibactam)

  1. ZAVICEFTA. Summary of Product Characteristics (Great Britain)
  2. Liscio JL, et al. Int J Antimicrob Agents 2015;46:266–7
  3. Nicolau DP, et al. J Antimicrob Chemother 2015;70:2862–9
  4. Mazuski JE, et al. Surg Infect 2017;18:1–76
  5.  ZAVICEFTA. Summary of Product Characteristics (Northern Ireland)
PP-ZVA-GBR-1546. May 2022

Learn more about the tolerability data of ZAVICEFTA from four Phase III clinical trials.

View tolerability profile

Quick Links

  • Patient Risk Factors

  • Pathogen Coverage

  • AMS Resources

Ask Zavibot a Question

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021



OK, We will need you to sign in before we can determine if you are aligned with a Pfizer promotional colleague.This is an interstitial message to prompt a HCP before they login.

If you have already registered with and select ‘yes’, you will be directed to the sign-in page where you will be required to enter your username and password.

Would you like to register or sign in now?